Patents by Inventor Satoru UJIHARA

Satoru UJIHARA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound, And Method For Producing Regulatory T Cells
    Publication number: 20230111840
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Application
    Filed: December 7, 2022
    Publication date: April 13, 2023
    Applicants: Kyoto University, Astellas Pharma Inc.
    Inventors: Shimon SAKAGUCHI, Naganari OHKURA, Norihisa MIKAMI, Shuh NARUMIYA, Masahiko AKAMATSU, Guliang XIA, Hironori HARADA, Naoto NAKAMURA, Satoru UJIHARA, Hisao HAMAGUCHI
  • Compound, and method for producing regulatory T cells
    Patent number: 11578067
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 14, 2023
    Assignees: KYOTO UNIVERSITY, ASTELLAS PHARMA INC.
    Inventors: Shimon Sakaguchi, Naganari Ohkura, Norihisa Mikami, Shuh Narumiya, Masahiko Akamatsu, Guliang Xia, Hironori Harada, Naoto Nakamura, Satoru Ujihara, Hisao Hamaguchi
  • Novel Compound, And Method For Producing Regulatory T Cells
    Publication number: 20190382403
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Application
    Filed: January 30, 2018
    Publication date: December 19, 2019
    Applicants: Kyoto University, Astellas Pharma Inc.
    Inventors: Shimon SAKAGUCHI, Naganari OHKURA, Norihisa MIKAMI, Shuh NARUMIYA, Masahiko AKAMATSU, Guliang XIA, Hironori HARADA, Naoto NAKAMURA, Satoru UJIHARA, Hisao HAMAGUCHI